Y-mabs Therapeutics
Clinical trials sponsored by Y-mabs Therapeutics, explained in plain language.
-
Experimental cancer therapy targets tough tumors with radioactive precision
Disease control TerminatedThis early-stage trial tested a two-step radioimmunotherapy combining GD2-SADA and 177Lu-DOTA in patients with recurrent or metastatic solid tumors, including small cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma. The goal was to assess safety and find the right …
Phase: PHASE1 • Sponsor: Y-mAbs Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental lymphoma therapy tested in tiny early trial
Disease control TerminatedThis phase 1 trial tested a two-step radioimmunotherapy (CD38-SADA and 177Lu-DOTA) in patients with relapsed or refractory non-Hodgkin lymphoma. The goal was to find safe doses and dosing schedules. Only 1 participant was enrolled, and the study was terminated early, so no conclu…
Phase: PHASE1 • Sponsor: Y-mAbs Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC